EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, PGEN: Precigen Inc

04 Nov 25 15:59
LAST:

3.880

CHANGE:
 0.28		OPEN:
4.020		HIGH:
4.150		ASK:
0.000		VOLUME:
2.07M
CHG(%):
6.73		PREV:
4.160		LOW:
3.855		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
04 Nov 254.0204.1503.8603.8802.4M
03 Nov 254.1304.3504.0444.1605.67M
31 Oct 254.0404.1503.9504.1406.4M
30 Oct 253.9304.0803.9304.0502.07M
29 Oct 254.0504.0903.9354.0102.14M
28 Oct 254.2804.3503.9604.0602.7M
27 Oct 254.4004.4204.1904.3002.79M
24 Oct 254.3304.5154.2804.3303.74M
23 Oct 253.8804.2703.8804.2506.53M
22 Oct 254.1204.1803.8503.9104.32M

COMPANY PROFILE

Name:Precigen Inc
About:Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis; and AG019, which is in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Sector:Healthcare
Industry:Biotechnology
Address:20374 Seneca Meadows Parkway, Germantown, MD, United States, 20876
Website:https://precigen.com
CUSIP:74017N105
CIK:0001356090
ISIN:US74017N1054
FIGI:BBG000QL8VH9
LEI:549300XCWNQU35K64G19

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-8.85 
Forward P/E:-18.82 
PEG Ratio:0.15 
Price to Sales:336.65 
Price to Book:-33.53 
Profit Margin:-0.09 
Operating Margin:-32.54 
Return on Assets:-0.67 
Return on Equity:-6.68 
EPS Ratio:-0.41 
Revenue:4.34M 
Shares:352.91M 
Market Cap:1.369B 

TECHNICAL INDICATORS

MA5:4.054.3%
MA10:4.115.9%
MA20:3.802.0%
MA50:3.870.4%
MA100:2.8934.2%
MA200:2.2275.0%
STO14:38.05
RSI14:58.37
WPR14:-53.57
MTM14:0.39
ROC14:0.11 
ATR:0.30 
Week High:4.3512.1%
Week Low:3.860.5%
Month High:4.5216.4%
Month Low:2.9975.0%
Year High:5.2334.7%
Year Low:0.65495.7%
Volatility:59.18